NAD+
Nicotinamide adenine dinucleotide — a coenzyme rather than a true peptide, included here because it is marketed alongside them; sold as a supplement and used in some compounded preparations, where eligibility and form are questions for a licensed pharmacy.
What it is
NAD+ (nicotinamide adenine dinucleotide) is not actually a peptide — it's a coenzyme central to cellular energy metabolism, included in this library because the wellness market sells it alongside peptides through the same clinics and IV bars.
Cellular NAD+ levels decline with age, which powers an enormous supplement and infusion industry built on precursors (NR, NMN) and IV NAD+ drips. The human outcome evidence remains thin: precursor trials show raised NAD+ blood levels with, so far, modest and inconsistent clinical endpoints; IV NAD+ therapy has essentially no controlled-trial support.
What researchers have actually studied it for
Cellular energy metabolism and aging biology; human trials of precursors show biomarker changes with limited clinical endpoints so far.
How it works
NAD+ is the cell's electron shuttle — the redox currency of turning food into ATP — and the required substrate for sirtuins and PARPs, enzyme families central to metabolic regulation and DNA repair. The aging hypothesis: restore declining NAD+, restore those enzymes' headroom. The hypothesis is elegant; the human proof is pending.
Where it came from
Discovered in 1906 and central to twentieth-century biochemistry (multiple Nobel prizes touch it), NAD+ re-entered popular culture through 2010s sirtuin and NMN/NR longevity research. The IV-drip wellness industry grew out of that headline science — far ahead of its clinical results.
What the research record actually contains
- Deep foundational biochemistry — among the most-studied molecules in biology.
- Human precursor trials (NR, NMN): reliably raise blood NAD+; clinical endpoints modest and inconsistent so far.
- IV NAD+ therapy: essentially no controlled trials behind the marketed benefits.
What's known about risks
Oral precursors have reasonable short-term safety data at studied doses. IV NAD+ is known mostly for infusion discomfort and for lacking controlled characterization; 'natural molecule' does not annul the difference between physiology and a drip.
Where it stands legally
Sold as dietary supplements (precursors) and via compounded/infusion channels (IV NAD+), where eligibility and preparation standards are pharmacy questions. No NAD+ product is an approved anti-aging drug.
Worth asking a licensed provider
- 1.What outcome am I buying — and does any controlled trial connect this form of NAD+ to it?
- 2.If energy is my complaint, what work-up should come before a drip?
- 3.Do oral precursors at studied doses make more sense than infusions, if anything?